Abstract:Zehra Edis, 1, 2, * Junli Wang, 3, * Muhammad Khurram Waqas, 4 Muhammad Ijaz, 5 Munazza Ijaz 6 1 Department of Pharmaceutical Sciences,College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates; 2 Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates; 3 Laboratory of Reproduction and Genetics, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, People's Republic of China; 4 Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan; 5 Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore, Pakistan; 6 Institute of Molecular Biology and Biotechnology, The University of Lahore, Defense Road Campus, Lahore, Pakistan *These authors contributed equally to this work Correspondence: Munazza Ijaz Institute of Molecular Biology and Biotechnology, The University of Lahore, Defense Road Campus, Lahore, 54000, Pakistan Email munazza3murtaza@gmail.com Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers have been developing technological advances for significant progress in the oncotherapy by enabling the delivery of chemotherapeutic agents at increased drug content levels to the targeted spots. Several nano-drug delivery systems designed for tumor-targeting are evaluated in preclinical and clinical trials and showed promising outcomes in cancerous tumors' clinical management. This review describes nanocarrier's importance in managing different types of cancers and emphasizing nanocarriers for drug delivery and cancer nanotherapeutics. It also highlights the recent advances in nanocarriers-based delivery systems, including polymeric nanocarriers, micelles, nanotubes, dendrimers, magnetic nanoparticles, solid lipid nanoparticles, and quantum dots (QDs). The nanocarrier-based composites are discussed in terms of their structure, characteristics, and therapeutic applications in oncology. To conclude, the challenges and future exploration opportunities of nanocarriers in chemotherapeutics are also presented. Keywords: nanomaterials, anticancer agents, recent advances, multidrug resistance, chemotherapy

Versatile Delivery Systems for Non-Platinum Metal-Based Anticancer Therapeutic Agents

[Mutation of Streptococcus mutans. 1. A mutant without the major virulent factor].

Construction of Arsenic-Metal Complexes Loaded Nanodrugs for Solid Tumor Therapy: A Mini Review.

Recent Advances in Nanocarriers for Clinical Platinum(ii) Anticancer Drugs

Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs

Self-assembled polymer nanostructures for delivery of anticancer therapeutics

New Strategies and Trends for the Design of Metal-Based Anticancer Drugs

The limiting efficiency of four-band cells revisited

Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview

Recent Advances in Ruthenium and Platinum Based Supramolecular Coordination Complexes for Antitumor Therapy

Ruthenium-based Antitumor Drugs and Delivery Systems from Monotherapy to Combination Therapy

Nanoparticle-based materials in anticancer drug delivery: Current and future prospects

Highly effective poly(ethylene glycol) architectures for specific inhibition of immune receptor activation.

Targeted Drug Delivery System for Platinum-based Anticancer Drugs

Engineering carbon-based nanomaterials for the delivery of platinum compounds: An innovative cancer disarming frontier

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Volume-dependent essential and steroid hypertension.

Targeting and Delivery of Platinum-Based Anticancer Drugs.

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

Biomedical applications of multinuclear Pt(II)/Ru(II)/Ir(III) metallo-supramolecular assemblies for intensive cancer therapy

Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives